Respira is a clinical-stage inhaled therapeutics company developing next-generation pulmonary targeted therapeutics to address significant unmet patient needs in cardio-pulmonary diseases. Our lead program is in Phase 2 clinical testing for the treatment of pulmonary arterial hypertension (PAH).
With our first product partnered, industry-leading expertise in inhaled drug formulation and product development, and broad management experience in company-building, Respira is positioned for future success.Our lead product candidate, RT234, is in Phase 2 clinical development for treating symptoms of pulmonary arterial hypertension (PAH).
With our first product partnered, industry-leading expertise in inhaled drug formulation and product development, and broad management experience in company-building, Respira is positioned for future success.Our lead product candidate, RT234, is in Phase 2 clinical development for treating symptoms of pulmonary arterial hypertension (PAH).
Services
Respira develops unique inhaled therapeutic products that address significant unmet patient needs. Respira applies industry-leading experience and expertise to develop pulmonary products that have a high probability of technical and clinical success. Our initial focus is on 505b2 products that we believe will improve the standard of care.
Respira combines proprietary dry-powder inhaler device technologies and advanced particle engineering-based inhaled drug formulation approaches to develop novel therapeutics that deliver the drug where it needs to be-in the lung and lung periphery, instead of in the oropharyngeal cavity. Respira can deliver pure drug, carrier-blended, and particle-engineered formulations over a wide range of drug-powder payloads and molecule types.
Respira is developing next-generation cardiopulmonary disease-targeted inhalation products that enhance drug delivery to the lung periphery. Our approach combines Respira's state-of-the-art AOS dry-powder inhaler device and proprietary inhaled drug formulation technologies to enhance dose consistency and drug targeting to the small airways of the lung.
Reviews
Be the first to review Respira Therapeutics.
Write a Review
